Real-World Data Shows Lurbinectedin Beneficial for Pretreated SCLC and Mesothelioma
Lurbinectdin offers clinical benefit for heavily pretreated patients with small cell lung cancer (SCLC) and malignant pleural mesothelioma (MPM), according to real-world data presented by Daphne Dumoulin, MD, Erasmus MC Cancer Institute, Rotterdam, Netherlands, at the 2021 IASLC World Conference on Lung Cancer.
“Lurbinectedin, a selective inhibitor of oncogenic transcription is currently being investigated in patients with small cell lung cancer or malignant pleural mesothelioma after failure of at least first-line therapy, with phase 2 studies showing promising results,” explained Dr Dumoulin et al.
A total of 95 patients (43 SCLC, 55MPM) were treated with lurbinectedin between November 2019 and December 2020. All SCLC received lurbinectedin as third or further line of therapy and the median number of cycles administered in the SCLC group was 2 (range 1-12). Furthermore, 81% of MPM patients received lurbinectedin as third or further line of therapy, while ith the median number of cycles administered was 3.
Following 12 weeks, the disease control rate (DCR) and objective radiological response (ORR) in the SCLC arm were 29% and 17%, respectively. The median progression-free survival (PFS) was 1.5 months (95% CI: 1.4–3.0), and the median overall survival (OS) was 7.0 months (95% CI: 4.7-not reached).
Additionally, the MPM arm saw a DCR of 32%, no tumor responses were registered. The median PFS and OS was 2.8 months (95% CI: 1.4–4.2) and 7.2 months 95% CI: 5.9–not reached), respectively.
Lurbinectedin was well-tolerated amongst patients, with dose reductions applied to 27% - mainly due to fatigue or hematologic toxicity.
“Lurbinectedin appears to be a clinically meaningful therapeutic option in heavily pre-treated patients with SCLC and mesothelioma,” concluded Dr Dumuoulin and colleagues. —Alexandra Graziano
Dumuoulin, DW, et al. Lurbinectedin in pre-treated patients with small cell lung cancer and malignant pleural mesothelioma in a real-world setting. Presented at: the 2021 IASLC World Conference on Lung Cancer; September 8-14, 2021; virtual.
